AIM Vaccine Confirms Stable Share Capital and Meets Public Float Requirement in October 2026 Filing

Bulletin Express
Nov 03

AIM Vaccine Co., Ltd. (AIM Vaccine) reported no changes in its share structure for the month ended 31 October 2026, according to the company’s monthly return submitted to Hong Kong Exchanges and Clearing on 3 November 2026.

Registered Capital • H Shares: 507.67 million shares at RMB 1 par value each, unchanged from the prior month. • Domestic Shares: 718.89 million shares at RMB 1 par value each, also unchanged. • Total registered share capital remained RMB 1.23 billion.

Issued Shares and Public Float • Issued H Shares (stock code 06660) totaled 507.67 million, with no treasury shares outstanding. • Issued Domestic Shares were steady at 718.89 million. • The company confirmed compliance with the Hong Kong Main Board’s minimum 25% public-float requirement.

Capital Movements • No issuance, cancellation, repurchase, or conversion of shares occurred during October. • There were no outstanding share options, warrants, convertibles, or other agreements that could dilute current share capital. • The company reported no Hong Kong Depositary Receipts.

Governance Confirmation Company Secretary Liu Ling affirmed that all listing rule obligations and regulatory requirements related to the issuer’s securities continue to be satisfied.

With registered and issued share counts unchanged and full adherence to public-float rules, AIM Vaccine’s capital structure remained stable through October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10